Fortis Healthcare Ltd. share price target

*over or under performance to benchmark index Diagnostics business gross revenue rose 11.1% YoY to Rs. 387cr, driven by portfolio expansion, improving customer touchpoints and sustained traction across preventive and core testing segments. EBITDA increased 22.2% YoY to Rs. 532cr, while EBITDA margin expanded 80bps to 22.5%, driven by operating leverage, better hospital profitability and continued improvement in diagnostic business execution...

We recommend a BUY with a target price of Rs 1,038, implying an upside of ~10% from the CMP.

Fortis Healthcare (FORH) reported another strong quarter with EBITDA of Rs5.1bn in Q3FY26, up 35% YoY. Though hospital margin has improved by 550bps bps YoY over FY23-9MFY26 to 23%, we see further scope for improvement aided by 1) improving case and payor mix, 2) cost rationalization initiatives and ramp-up of Manesar and Greater Noida unit, and 3) new brownfield bed additions. Additionally, we expect margin to expand further,...

We maintain a BUY rating on Fortis Healthcare with a target price of Rs 1,070/share

400-500 beds, supported by capacity expansion in Noida and Jalandhar. Fortis is targeting an EBITDA margin of 25% in the hospital business for the next couple of years. Additionally, the international patients segment is...

Fortis Healthcare (Fortis) delivered a strong beat in EBITDA and PAT led by stronger margins across its hospitals (+140bps) and diagnostic verticals (+510bps).

We maintain a BUY rating on Fortis Healthcare with a target price of Rs 1,070/share

We maintain a BUY rating on Fortis Healthcare with a target price of Rs 1,000/share.

Fortis Healthcare (FORH) reported strong EBITDA of Rs4.9bn, up 43% YoY, marking strong beat across segments. Though hospital margin has improved by 360bps bps YoY over FY23-25 to ~20%, we see further scope for improvement aided by 1) improving case and payor mix, 2) cost rationalization initiatives and ramp-up of Manesar unit, and 3) new brownfield bed additions. Additionally, we expect margin to expand further, driven by the recent...

Fortis Healthcare's (FORH) Q4FY25 EBITDA at Rs4.36bn; up 14% YoY was in line with our estimates. Though hospital margins improved by 170bps/190bps YoY in FY24/FY25, we see further scope for improvement aided by 1) improving case and payor mix, 2) cost rationalization initiatives including divestment of Richmond unit in Bangalore, ramp up of Manesar unit and 3) new brownfield bed additions. Fortis consolidated 89.2% stake in Agilus in Jan'25. We expect...

We recommend a BUY rating on the stock with a target price of Rs 693/share, implying an upside of 10% from the CMP

We maintain a BUY rating on Fortis Healthcare with a target price of Rs 860/share.

We recommend Fortis Healthcare Ltd. with a BUY rating and a target price of Rs 860/share, indicating a 20% upside from the CMP.